<DOC>
	<DOC>NCT00701805</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of paricalcitol injection. Subjects will administer clinical supplies 3 times a week, 40 weeks at dialysis session in dose-titration manner, following 12 weeks of treatment in the dose-response study, M10-309 (NCT00667576).</brief_summary>
	<brief_title>Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)</brief_title>
	<detailed_description>The first 12-week period in this study was a dose-response study reported as Study M10-309 (NCT00667576). Only subjects who completed 12 weeks in NCT00667576 were enrolled into this study (M10-312). Baseline in this study was the same as Baseline in NCT00667576. The duration of treatment in Study M10-312 was 40 weeks (for a total of 52 weeks, including NCT00667576).</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients who completed 12 weeks of Study M10309 (NCT00667576). Patients taking drugs that affect intact parathyroid hormone (iPTH), calcium, or bone metabolism. Patients with progressive malignancy or clinically significant hepatic disease. Patients who developed severe cerebrovascular/cardiovascular disease during the doseresponse portion of the study (i.e., during M10309, NCT00667576). Patients with uncontrolled diabetes during the doseresponse portion of the study (i.e., during M10309, NCT00667576).</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Secondary hyperparathyroidism</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>paricalcitol</keyword>
</DOC>